Cellavision Ab · OMXSTO:CEVI
Cellavision Ab — Investor Presentation (April 2010)
18 slides from Cellavision Ab's investor presentation, Apr 29, 2010
Slide 1: CellaVision, April 29, 2010
CellaVision, April 29, 2010 Yvonne Mårtensson, CEO
Slide 2: Introduction
Introduction CellaVision is world leader in a market with large potential, offering automated digital cell morphology The hematology analysis market comprises more than 1 billion CBC tests a year – manual differential work equivalent to more than USD 1 billion CellaVision’s market includes products
Slide 3: Global customer base
Global customer base More than 700 systems mainly in Europe and North America Hospital and commercial hematology laboratories The hospital demand for efficiency and cost reduction makes automation the obvious choice The labor shortage of biomedical scientists is a market driver 3
Slide 4: Our unique technology adds value
Our unique technology adds value Efficiency cost reduction and increased productivity Proficiency increased quality of results Connectivity between sites; enhanced opportunity for collaboration and sharing of competences 4
Slide 5: 37 Nordic customers
37 Nordic customers Finland Helsinki Island Norge Sverige Reykjavik Trondheim Uppsala Stavanger Karolinska Nya Ahus Huddinge Danderyd Södersjukhuset Linköping Jönköping Trollhättan Sahlgrenska Östra Sjukhuset Borås Varberg Halmstad Danmark Växjö Aalborg Västervik Aarhus Kalmar Odense Karlskrona Sven
Slide 6: Network capabilities give staffing flexibility
Network capabilities give staffing flexibility Södra Älvsborg Sahlgrenska University Sahlgrenska University County Hospital Hospital Östra Hospital Norra Älvsborg County Hospital ―Nine laboratories will cooperate 6
Slide 7: CellaVision in short
CellaVision in short Sales through Sysmex and Beckman Coulter. Direct sales through subsidiaries in the Nordic countries, the US, Canada and Japan Headquarters in Lund, Sweden 50 employees Manufacturing outsourced to Kitron AB, Karlskoga, Sweden 18 patented innovations Competition: manual microscopy
Slide 8: CellaVision's product offering
CellaVision’s product offering Analysis instruments CellaVision® DM8 CellaVision® DM96 CellaVision® DM1200 Optional application for body fluids analysis CellaVision® Body Fluid Application Software for networking and remote access CellaVision® Remote Review Software Software for proficiency testing
Slide 9: Financial performance 2001–2009
Financial performance 2001–2009 MSEK FTEs 9
Slide 10: Net sales by geographic area
Net sales by geographic area 2009 2008 10
Slide 11: Achievements 2009
Achievements 2009 @ CELLAVISION 6
Slide 12: Achievements 2009
Achievements 2009 Third consecutive year of profitability Net sales increased by 8 % to SEK 109.0 million (100.4) The operating result increased to SEK 14.8 million (13.4) Profit before income tax increased to SEK 14.2 million (13.1) The net result per share amounted to SEK 1.16 (1.05) Cash and cash
Slide 13: Important events Q1 2010
Important events Q1 2010 Strengthening presence in the US by entering an agreement with Beckman Coulter, market leading in analyzers for hematology and clinical diagnostics Board of Directors plans for a listing on NASDAQ OMX Stockholm, Small Cap Extending and broadening cooperation with Sysmex by e
Slide 14: Q1 2010 report in summary
Q1 2010 report in summary New distribution strategy provides enhanced growth opportunities Net sales amounted to SEK 21.1 million (22.0) The operating result was SEK -4.4 million (0.9) The net result amounted to SEK -4.7 million (0.5) Cash and cash equivalents amounted to SEK 18.0 million (14.5) by
Slide 15: CellaVision going forward
CellaVision going forward Hematology Business Continue global market penetration in Europe, the US and Asia, with focus on North America and Japan Refine business model to achieve more recurring revenue. Model under test in Canada Software development, new applications like bone marrow Other Busines
Slide 16: Shareholders
Shareholders Shareholder No. of shares % The share Listed on NASDAQ OMX First H&B Capital LP 4,073,139 17.1 North since May 2007. Entered the segment Premier in Feb 2009 Stiftelsen Industrifonden 3,587,257 15.0 Ticker symbol: CEVI More than 1,300 shareholders Metallica Förvaltnings AB 2,738,967 11.5
Slide 17: Share price development since 1 Jan 2009
Share price development since 1 Jan 2009 SEK (rebased to CellaVision) Volume (’000) 20 180 18 160 16 140 14 120 12 100 10 80 8 60 6 40 4 2 20 0 0 Jan-09 Feb-09 Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10 Apr-10 Volume - CellaVision Price - CellaVision (
Slide 18: For more information, please visit www.cellavision.com
For more information, please visit www.cellavision.com 18